Overview
- First of its kind to integrate precision medicine, biopharmaceutics, and translational approaches
- Industry performance sets the stage and highlights the need for greater discovery/development integration to improve the efficiency and success rate of bring new medicines to patients
- Describes how the discovery and developmental environments can learn from each other and leverage each other’s strengths
Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series (AAPS, volume 25)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (14 chapters)
-
Front Matter
-
Discovery, Development and Commercialization of Drug Candidates: Overview and Issues
-
Front Matter
-
-
Druggable Targets, Discovery Technologies and Generation of Lead Molecules
-
Front Matter
-
-
Optimizing Lead Molecules into Drug Candidates
-
Front Matter
-
-
Early Clinical Development of Drug Candidates
-
Front Matter
-
-
Evolution of the Drug Discovery/Development Paradigm
-
Front Matter
-
Keywords
About this book
Editors and Affiliations
About the editors
John S. Morrison earned his doctorate in physical organic chemistry from the University of Western Ontario studying the photochemical mechanisms responsible for the light-struck reaction in beer. After graduation John joined the Preformulation and Analytical Method Development group of Apotex Inc evaluating drug substances and novel drug product formulations. He then transitioned to the Discovery Pharmaceutics group of Bristol-Myers Squibb characterizing early drug candidates and establishing delivery strategies for a variety of dosing routes and molecular modalities. His current role bridges the discovery/development divide, collaboratively supporting multi-disciplinary discovery teams as well as determining and mitigating developability risks for potential clinical drug candidates. John has also led several AAPS committees and co-organizes the ACS Drug Design and Delivery webinar series.
David M. Bender is a Senior Research Scientist in Small Molecule Design and Development at Eli Lilly and Co. He received a B.S in chemistry from Miami University and an M.S. in organic chemistry from Colorado State University where he conducted research into the design and synthesis of novel antibacterial agents. He joined Eli Lilly and Co. in 1998 as a synthetic organic chemist in Discovery Chemistry Research. In 2009, he joined the Product Research and Development organization, where he has focused on formulation development, small molecule developability, absorption modeling and alternate drug delivery. Mr. Bender is currently a group leader in the Product Design and Developability group, and is responsible for overseeing the design and manufacture of clinical drug product for small molecules entering Lilly’s development pipeline.
Daniel R. Mudra is Director of ADME at Eli Lilly and Company. He earned his B.S. from The University of Dayton studying pharmacokinetic/pharmacodynamic effects of drug-impregnated implants and an M.S. from Loyola University Chicago investigating the biochemical regulation of the p38 kinase pathway. He earned his doctorate in Pharmaceutical Chemistry from The University of Kansas developing in situ and computational models of absorption studying the effects of excipients on permeability, metabolism and transport. Dr. Mudra began his industrial research career at XenoTech, LLC and has published on models of P450 induction and inhibition, drug absorption and PK. Since joining Lilly, he has contributed to projects from target identification to clinical development across a variety of therapeutic areas. He leads in the incorporation of mechanistic and physiologically based PK modeling including the use of molecular attributes to predict human clearance pathways.
Bibliographic Information
Book Title: Translating Molecules into Medicines
Book Subtitle: Cross-Functional Integration at the Drug Discovery-Development Interface
Editors: Shobha N. Bhattachar, John S. Morrison, Daniel R. Mudra, David M. Bender
Series Title: AAPS Advances in the Pharmaceutical Sciences Series
DOI: https://doi.org/10.1007/978-3-319-50042-3
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: American Association of Pharmaceutical Scientists 2017
Hardcover ISBN: 978-3-319-50040-9Published: 03 May 2017
Softcover ISBN: 978-3-319-84303-2Published: 20 July 2018
eBook ISBN: 978-3-319-50042-3Published: 21 April 2017
Series ISSN: 2210-7371
Series E-ISSN: 2210-738X
Edition Number: 1
Number of Pages: XXIV, 461
Number of Illustrations: 20 b/w illustrations, 81 illustrations in colour